Key Highlights
- Replimune Group shares closed up 9% at $12.86.
- The FDA granted accelerated approval for TUDRIQEV in combination with nivolumab.
- The approval covers unresectable advanced cutaneous melanoma following anti-PD-1 progression.
- The approval was supported by IGNYTE trial data showing a 24.2% objective response rate.
Replimune Group, Inc. (NASDAQ: REPL) shares closed up 9% at $12.86 after the company disclosed that the FDA has granted accelerated approval for TUDRIQEV in combination with nivolumab for the treatment of patients with unresectable advanced cutaneous melanoma following anti-PD-1 progression.
What Happened
The regulatory milestone was supported by IGNYTE trial data, which demonstrated a 24.2% objective response rate and a 14.1-month median duration of response.
Market Reaction
Shares rose as investors responded to the accelerated approval, though sustained approval for this indication remains contingent upon verification of clinical benefit in confirmatory studies.
Outlook
Completion of the required confirmatory studies verifying clinical benefit is likely to remain the key regulatory milestone determining the durability of TUDRIQEV's accelerated approval.
Why did Replimune Group shares rise 9%?
Shares rose after the FDA granted accelerated approval for TUDRIQEV in combination with nivolumab for advanced cutaneous melanoma.
What data supported the approval?
IGNYTE trial data showing a 24.2% objective response rate and a 14.1-month median duration of response.
Is this approval permanent?
No, sustained approval remains contingent upon verification of clinical benefit in confirmatory studies.






Please wait processing your request...